Cell and Gene Therapies
Revolutionary treatments using genetic engineering and cellular reprogramming
Advanced Cell & Gene Therapy Platform
Oracle BioTech is at the forefront of developing next-generation cell and gene therapies using CRISPR gene editing, stem cell technology, and viral vector delivery systems.
Gene Editing Platform
CRISPR-Cas9 and base editing technologies for treating genetic disorders at their source.
- In vivo gene editing
- Ex vivo cell modification
- Prime editing technology
- Epigenome editing
CAR-T Cell Immunotherapy
Engineered T-cell therapies for hematologic malignancies and solid tumors.
- Next-generation CAR designs
- Universal CAR-T platforms
- Solid tumor targeting
- Safety switch technologies
Regenerative Medicine
Stem cell and tissue engineering solutions for degenerative diseases and organ repair.
- iPSC-derived therapies
- Mesenchymal stem cells
- Tissue scaffolding
- Organoid models
Cell & Gene Therapy Pipeline
Discovery
5 ProgramsNovel gene targets and delivery vector optimization.
Preclinical
4 ProgramsIn vivo efficacy and biodistribution studies.
Phase I
3 ProgramsFirst-in-human gene therapy safety studies.
Phase II
2 ProgramsProof-of-concept in genetic disease patients.
Phase III
1 ProgramRegistration-enabling study for inherited blindness gene therapy.
Manufacturing Excellence
GMP Manufacturing
State-of-the-art facilities for viral vector production and cell therapy manufacturing under cGMP conditions.
Quality Control
Comprehensive analytical testing and release assays ensuring product safety and potency.